

## THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The Phase III COSMIC-313 trial compared which of the following regimens as first-line therapy for patients with advanced renal cell carcinoma (RCC)?**
  - a. Cabozantinib to nivolumab
  - b. Pembrolizumab to placebo
  - c. Lenvatinib/pembrolizumab to sunitinib
  - d. Cabozantinib/nivolumab/ipilimumab to nivolumab/ipilimumab**
- 2. TAR-200 is an intravesical drug delivery device for...**
  - a. BCG immunotherapy
  - b. Gemcitabine**
  - c. Erdafitinib
  - d. Immunotherapy
  - e. I don't know
- 3. Which of the following statements best characterizes the activity observed in cohort K of the EV-103 study evaluating the combination of enfortumab vedotin and pembrolizumab for patients with previously untreated cisplatin-ineligible locally advanced or metastatic urothelial bladder cancer?**
  - a. Tumor reductions were observed in patients with a PD-L1 combined positive score (CPS) of  $\geq 5$  only
  - b. Tumor reductions were observed in patients with a PD-L1 CPS of  $\geq 10$  only
  - c. Tumor reductions were observed regardless of PD-L1 CPS**
- 4. TAR-200 is being evaluated in combination with which of the following agents as neoadjuvant therapy for patients with muscle-invasive bladder cancer in the Phase II SunRISe-2 trial?**
  - a. Erdafitinib
  - b. Nivolumab
  - c. Avelumab
  - d. Cetrelimab**
- 5. Which drug type best reflects the mechanism of action of disitamab vedotin (RC-48)?**
  - a. PARP inhibitor
  - b. Antibody-drug conjugate**
  - c. Anti-PD-1/PD-L1 antibody
  - d. Alkylating agent